|
Association of PSMA PET results at biochemical recurrence (BCR) with metastasis free survival (MFS) by conventional imaging (CI) in patients with locally advanced or high-risk localized prostate cancer initially treated with radical prostatectomy (RP): A retrospective multicenter study. |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Curium Pharma; RayzeBio |
Honoraria - GE Healthcare |
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Curium Pharma; Ipsen; ITM Isotope Technologies Munich; Lantheus Medical Imaging |
Research Funding - Advanced Accelerator Applications (Inst); Clovis Oncology (Inst); GE Healthcare (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Novartis (Inst); Philips Healthcare (Inst); Telix Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - GE Healthcare |
|
|
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals |
Speakers' Bureau - Lantheus Medical Imaging |
Research Funding - Progenics |
|
|
|
Consulting or Advisory Role - Calyx; GE Healthcare; Janssen; Lilly |
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Novartis; Telix Pharmaceuticals; Telix Pharmaceuticals |
Consulting or Advisory Role - ABX Advanced biochemical compounds; Blue Earth Diagnostics; Janssen Oncology; Novartis (Inst); Telix Pharmaceuticals |
Research Funding - ABX Advanced biochemical compounds; Bayer (Inst); Blue Earth Diagnostics (Inst); Siemens |
Patents, Royalties, Other Intellectual Property - patent application for rhPSMA |
Travel, Accommodations, Expenses - Bayer Schering Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Aktis Oncology; Pharma15 |
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Research Funding - Siemens Healthcare Diagnostics |
|
|
No Relationships to Disclose |
|
|
Employment - Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Johnson and Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Flatiron Health; Johnson & Johnson/Janssen |
Stock and Other Ownership Interests - Flatiron Health; Johnson & Johnson/Janssen; Roche Pharma AG |
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
Travel, Accommodations, Expenses - Janssen Research & Development |